Axa S.A. Astrazeneca PLC Transaction History

Axa S.A.

$33.1 Billion
Q2 2024

A detailed history of Axa S.A. transactions in Astrazeneca PLC stock. As of the latest transaction made, Axa S.A. holds 400,242 shares of AZN stock, worth $31.1 Million. This represents 0.09% of its overall portfolio holdings.

Number of Shares

400,242

Previous 35,121 1039.61%

Holding current value

$31.1 Million

Previous $2.38 Million 1212.06%

% of portfolio

0.09%

Previous 0.01%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$66.81 - $80.83 $24.4 Million - $29.5 Million	365,121 Added 1039.61%	400,242 $31.2 Million
Q1 2024 May 15, 2024	BUY	$61.03 - $69.57 $320,041 - $364,825	5,244 Added 17.55%	35,121 $2.38 Million
Q4 2023 Jul 16, 2024	SELL	$61.89 - $69.28 $324,551 - $363,304	-5,244 Reduced 14.93%	29,877 $2.01 Million
Q4 2023 Feb 14, 2024	BUY	$61.89 - $69.28 $312,915 - $350,279	5,056 Added 20.37%	29,877 $2.01 Million
Q3 2023 Nov 14, 2023	BUY	$64.85 - $71.7 $334,820 - $370,187	5,163 Added 26.26%	24,821 $1.68 Million
Q2 2023 Aug 14, 2023	SELL	$69.91 - $75.81 $489 - $530	-7 Reduced 0.04%	19,658 $1.41 Million
Q4 2022 Feb 14, 2023	BUY	$54.21 - $70.44 $1.07 Million - $1.39 Million	19,665 New	19,665 $1.33 Million
Q1 2022 May 13, 2022	SELL	$55.72 - $67.12 $33,822 - $40,741	-607 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$55.56 - $60.79 $33,724 - $36,899	607 New	607 $36,000
Q1 2021 May 14, 2021	SELL	$47.16 - $54.44 $91,914 - $106,103	-1,949 Closed	0 $0
Q4 2020 Feb 12, 2021	BUY	$48.52 - $58.02 $3,347 - $4,003	69 Added 3.67%	1,949 $97,000
Q3 2020 Nov 13, 2020	BUY	$53.07 - $61.1 $99,771 - $114,868	1,880 New	1,880 $103,000

Others Institutions Holding AZN

# of Institutions

1,333

Shares Held

490M

Call Options Held

4.99M

Put Options Held

3.19M

View Full List

About ASTRAZENECA PLC

Ticker AZN
Exchange OTC
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 3,099,020,032
Market Cap $241B
Description
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, By...

More about AZN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Axa S.A., based on Form 13F filings with the SEC.

News

Stay updated on Axa S.A. with notifications on news.

Account